Johnson & Johnson announced on Tuesday that Chief Scientific Officer Paul Stoffels, who led the company's single-shot COVID-19 vaccine development, will step down at the end of the year.
Stoffels' successor has yet to be named by the healthcare company.
Stoffels, 59, began his career as an HIV-focused physician in Africa and then worked for J&J's Janssen Pharmaceutica in the early 1990s. When J&J bought Virco and Tibotec, a Belgian antiviral medication researcher, in 2002 to broaden its HIV therapeutic pipeline, he rejoined the company.
Since 2012, Stoffels has served as Chief Scientific Officer, overseeing innovation and safety throughout J&J's pharmaceuticals, medical device, and consumer health businesses.
"The Janssen R&D teams developed more than 25 innovative medications across several therapeutic categories during Paul's leadership," stated Joaquin Duato, J&J's incoming CEO.
J&J named Duato as the long-serving Chief Executive Officer Alex Gorsky's successor in August, with an effective date of January 3.
During Stoffels' tenure, the company produced a COVID-19 one-shot vaccination, which received FDA approval in February. The vaccine's uptake, on the other hand, was hampered by safety concerns.